Allogeneic Hematopoietic Cell Transplantation clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for

  • Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    open to eligible people ages 18-75

    This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

    Sacramento, California and other locations

  • Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

    open to all eligible people

    The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.

    Sacramento, California and other locations

Last updated: